In8Bio (INAB) Operating Income (2020 - 2026)
In8Bio's (INAB) quarterly Operating Income came in at -$4.8 million in Q2 2026, up 6.14% year-over-year from -$4.5 million in Q2 2025, and up 6.07% quarter-over-quarter from -$5.1 million in Q1 2026.
Powered by 
Analysis
In8Bio (INAB) Operating Income (2020 - 2026) Analysis & Trends
In8Bio has disclosed Operating Income across 7 years of filings, most recently posting -$4.8 million for Q2 2026.
- In Q2 2026, Operating Income rose 6.14% year-over-year to -$4.8 million; the TTM figure through Jun 2026 stood at -$18.7 million (up 21.86% YoY), while the FY2025 annual figure was -$19.4 million, up 36.13% from the prior year.
- Operating Income came in at -$4.8 million for Q2 2026 at In8Bio, up from -$5.1 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$3.9 million in Q3 2025 to a low of -$8.6 million in Q2 2024.
- Average Operating Income over 5 years is -$6.6 million, with a median of -$7.1 million recorded in 2023.
- Year-over-year, Operating Income sank 160.05% in 2022 and soared 45.61% in 2025.
- Over 5 years, Operating Income stood at -$7.8 million in 2022, then grew by 2.56% to -$7.6 million in 2023, then grew by 18.93% to -$6.2 million in 2024, then grew by 19.77% to -$4.9 million in 2025, then grew by 3.26% to -$4.8 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$4.8 million in Q2 2026, -$5.1 million in Q1 2026, and -$4.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.25 Bn | 9.40 Bn | 112.79 Mn | 58.42 Mn |
| 2 | CRISPR Therapeutics AG | 5.06 Bn | 5.06 Bn | - | -117.27 Mn |
| 3 | Iovance Biotherapeutics | 3.74 Bn | 3.45 Bn | 55.72 Mn | -51.91 Mn |
| 4 | Legend Biotech | 3.58 Bn | 2.62 Bn | 251.50 Mn | 57.70 Mn |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | -52.20 Mn |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | -126.55 Mn |
| 7 | Precigen | 2.37 Bn | 2.37 Bn | 52.17 Mn | 22.64 Mn |
| 8 | Sarepta Therapeutics | 2.21 Bn | 1.42 Bn | 251.87 Mn | 13.29 Mn |
| 9 | Vericel | 1.95 Bn | 1.79 Bn | 56.40 Mn | 434,000.00 |
| 10 | In8Bio | 21.41 Mn | 21.41 Mn | - | -4.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.78 Mn |
| Mar 31, 2026 | -5.09 Mn |
| Dec 31, 2025 | -4.94 Mn |
| Sep 30, 2025 | -3.85 Mn |
| Jun 30, 2025 | -5.09 Mn |
| Mar 31, 2025 | -5.55 Mn |
| Dec 31, 2024 | -6.16 Mn |
| Sep 30, 2024 | -7.09 Mn |
| Jun 30, 2024 | -8.63 Mn |
| Mar 31, 2024 | -8.56 Mn |
| Dec 31, 2023 | -7.60 Mn |
| Sep 30, 2023 | -7.17 Mn |
| Jun 30, 2023 | -7.72 Mn |
| Mar 31, 2023 | -7.53 Mn |
| Dec 31, 2022 | -7.80 Mn |
| Sep 30, 2022 | -7.40 Mn |
| Jun 30, 2022 | -7.18 Mn |
| Mar 31, 2022 | -6.15 Mn |
| Dec 31, 2021 | -5.85 Mn |
| Sep 30, 2021 | -3.39 Mn |